HomeCompareBBI vs EPRT

BBI vs EPRT: Dividend Comparison 2026

BBI yields 85.11% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBI wins by $2.01M in total portfolio value
10 years
BBI
BBI
● Live price
85.11%
Share price
$2.35
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.08M
Annual income
$627,483.66
Full BBI calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — BBI vs EPRT

📍 BBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBIEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBI + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBI pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBI
Annual income on $10K today (after 15% tax)
$7,234.04/yr
After 10yr DRIP, annual income (after tax)
$533,361.11/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, BBI beats the other by $522,446.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBI + EPRT for your $10,000?

BBI: 50%EPRT: 50%
100% EPRT50/50100% BBI
Portfolio after 10yr
$1.07M
Annual income
$320,162.19/yr
Blended yield
29.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

BBI
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
-7.2
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBI buys
0
EPRT buys
0
No recent congressional trades found for BBI or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBIEPRT
Forward yield85.11%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$2.08M$63.4K
Annual income after 10y$627,483.66$12,840.73
Total dividends collected$1.82M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: BBI vs EPRT ($10,000, DRIP)

YearBBI PortfolioBBI Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$19,211$8,510.64$11,205$505.18+$8.0KBBI
2$35,835$15,279.89$12,672$682.46+$23.2KBBI
3$64,982$26,638.22$14,490$930.48+$50.5KBBI
4$114,675$45,144.37$16,786$1,282.69+$97.9KBBI
5$197,158$74,455.37$19,753$1,791.56+$177.4KBBI
6$330,593$119,634.65$23,677$2,541.64+$306.9KBBI
7$541,214$187,479.44$29,008$3,672.99+$512.2KBBI
8$865,943$286,843.50$36,463$5,425.08+$829.5KBBI
9$1,355,484$428,924.80$47,238$8,221.57+$1.31MBBI
10$2,077,851$627,483.66$63,385$12,840.73+$2.01MBBI

BBI vs EPRT: Complete Analysis 2026

BBIStock

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Full BBI Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this BBI vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBI vs SCHDBBI vs JEPIBBI vs OBBI vs KOBBI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.